DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02879409

Active not recruitingPhase NA

HbA1c Variability in Type II Diabetes

Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

150

estimated

Study population

Type 2 diabetes

Key I/E criteria

•BMI 26-36•HbA1c 7.5-9%

Primary endpoint

•Determination of the variability of HbA1c between the 2 diabetes treatment

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02879409
Org study ID14-00058
Secondary ID15103/15Hamad Medical Corporation
Secondary IDNPRP: 8-315-3-065Qatar National Research Fund

Timeline

Milestones

Study first posted2016-08-25estimated
Primary completion2023-10-01actual
Last update posted2025-07-20actual
Study completion2026-10-01estimated
Study start2016-11 (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Qatari subjects only with type 2 diabetes taking any medication.
•HbA1c 7.5-9.0%.
•Body mass index 26-36.
•Age 18 - 65 years of age.
•Recruitment of a gender balance reflecting the local eligible diabetes patients until 150 are recruited.

Exclusion criteria

•Patients with anemia or other conditions known to affect the validity of HbA1c measurement e.g. a haemoglobinopathy known to affect the Hamad HbA1c method or renal failure (CKD Stage 5)
•Patients with concurrent illness
•Patients on medication leading to insulin resistance e.g. corticosteroids
•Pregnancy
•Active retinopathy
•Any clinical exclusion for optimal diabetes control
•Hypoglycemic unawareness

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
2
Cardiometabolic biomarkers
1
Other (unclassified)
1

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

Determination of the variability of HbA1c (by measurement of standard deviation of HbA1c) between the 2 diabetes treatment thresholds

Time frame:24-30 months

descriptive

LOINC 4548-4

Secondary/protocol endpoint

Comparison of HbA1c (percent) for each subject at baseline and following sample storage of 2 years to assess HbA1c measurement stability.

Time frame:2-3 years.

descriptive

LOINC 4548-4

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint/low confidence

Association of the variability of HbA1c (by measurement of standard deviation of HbA1c) to oxidative stress markers measured by urinary isoprostanes and inflammation measured by highly sensitive C-reactive protein.

Time frame:24-30 months

hs-CRP, change

descriptive

LOINC 30522-7

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Association of the variability of HbA1c (by measurement of standard deviation of HbA1c) to microvascular changes in heart rate variability, corneal nerve fiber density, albumin/creatinine ratio and estimated glomerular filtration rate.

Time frame:24-30 months

descriptive

Publications (29)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.